Schlaganfall und Hirnblutung unter Antikoagulation oder Thrombozytenfunktionshemmung – wann und wie erneut starten?

Zurück zum Zitat Heuschmann PU, Busse O, Wagner M, Endres M, Villringer A, Röther J, Kolominsky-Rabas PL, Berger K, Kompetenznetz Schlaganfall dDSGsdSD, Schlaganfall-Hilfe (2010) Schlaganfallhäufigkeit und Versorgung von Schlaganfallpatienten in Deutschland (frequency and care of stroke in Germany). akt Neurol 37:333–340CrossRef Heuschmann PU, Busse O, Wagner M, Endres M, Villringer A, Röther J, Kolominsky-Rabas PL, Berger K, Kompetenznetz Schlaganfall dDSGsdSD, Schlaganfall-Hilfe (2010) Schlaganfallhäufigkeit und Versorgung von Schlaganfallpatienten in Deutschland (frequency and care of stroke in Germany). akt Neurol 37:333–340CrossRef

Zurück zum Zitat Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbuchel H (2018) The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39:1330–1393CrossRef Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbuchel H (2018) The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39:1330–1393CrossRef

Zurück zum Zitat Diener H, Endres M, Röther J (2015) S 3 Leitlinie „Sekundärprophylaxe ischämischer Schlaganfall und transitorische ischämische Attacke“ – Teil 1 (AWMF-Registernummer 030-133 www.awmf.org) Diener H, Endres M, Röther J (2015) S 3 Leitlinie „Sekundärprophylaxe ischämischer Schlaganfall und transitorische ischämische Attacke“ – Teil 1 (AWMF-Registernummer 030-133 www.​awmf.​org)

Zurück zum Zitat ATC. Antithrombotic trialists’ collaboration. (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic trialists’ collaboration. BMJ 324(7330):141CrossRef ATC. Antithrombotic trialists’ collaboration. (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic trialists’ collaboration. BMJ 324(7330):141CrossRef

Zurück zum Zitat Rothwell PM, Algra A, Chen Z, Diener HC, Norrving B, Mehta Z (2016) Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 388:365–375CrossRef Rothwell PM, Algra A, Chen Z, Diener HC, Norrving B, Mehta Z (2016) Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 388:365–375CrossRef

Zurück zum Zitat Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY (2018) Clopidogrel and aspirin in acute ischemic stroke and high-risk tia. N Engl J Med 379:215–225CrossRef Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY (2018) Clopidogrel and aspirin in acute ischemic stroke and high-risk tia. N Engl J Med 379:215–225CrossRef

Zurück zum Zitat Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KS (2016) Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 375:35–43CrossRef Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KS (2016) Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 375:35–43CrossRef

Zurück zum Zitat Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y (2019) The acute stroke or transient ischemic attack treated with ticagrelor and aspirin for prevention of stroke and death (thales) trial: rationale and design. Int J Stroke 14:745–751CrossRef Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y (2019) The acute stroke or transient ischemic attack treated with ticagrelor and aspirin for prevention of stroke and death (thales) trial: rationale and design. Int J Stroke 14:745–751CrossRef

Zurück zum Zitat Klijn CJM, Paciaroni M, Berge E, Korompoki E, Korv J, Avtar L, Putaala J, Werring DJ (2019) Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A european stroke organisation guideline. Eur Stroke J 4(3):198–223. https://doi.org/10.1177/2396987319841187 CrossRefPubMedPubMedCentral Klijn CJM, Paciaroni M, Berge E, Korompoki E, Korv J, Avtar L, Putaala J, Werring DJ (2019) Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A european stroke organisation guideline. Eur Stroke J 4(3):198–223. https://​doi.​org/​10.​1177/​2396987319841187​ CrossRefPubMedPubMedCentral

Zurück zum Zitat Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P (2015) Updated european heart rhythm association practical guide on the use of non-vitamin k antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17:1467–1507CrossRef Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P (2015) Updated european heart rhythm association practical guide on the use of non-vitamin k antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17:1467–1507CrossRef

Zurück zum Zitat Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, Flechsenhar J, Neugebauer H, Juttler E, Grau A, Palm F, Rother J, Michels P, Hamann GF, Huwel J, Hagemann G, Barber B, Terborg C, Trostdorf F, Bazner H, Roth A, Wohrle J, Keller M, Schwarz M, Reimann G, Volkmann J, Mullges W, Kraft P, Classen J, Hobohm C, Horn M, Milewski A, Reichmann H, Schneider H, Schimmel E, Fink GR, Dohmen C, Stetefeld H, Witte O, Gunther A, Neumann-Haefelin T, Racs AE, Nueckel M, Erbguth F, Kloska SP, Dorfler A, Kohrmann M, Schwab S, Huttner HB (2015) Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 313:824–836CrossRef Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, Flechsenhar J, Neugebauer H, Juttler E, Grau A, Palm F, Rother J, Michels P, Hamann GF, Huwel J, Hagemann G, Barber B, Terborg C, Trostdorf F, Bazner H, Roth A, Wohrle J, Keller M, Schwarz M, Reimann G, Volkmann J, Mullges W, Kraft P, Classen J, Hobohm C, Horn M, Milewski A, Reichmann H, Schneider H, Schimmel E, Fink GR, Dohmen C, Stetefeld H, Witte O, Gunther A, Neumann-Haefelin T, Racs AE, Nueckel M, Erbguth F, Kloska SP, Dorfler A, Kohrmann M, Schwab S, Huttner HB (2015) Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 313:824–836CrossRef

Zurück zum Zitat Al-Shahi Salman R, Minks DP, Mitra D, Rodrigues MA, Bhatnagar P, du Plessis JC, Joshi Y, Dennis MS, Murray GD, Newby DE, Sandercock PAG, Sprigg N, Stephen J, Sudlow CLM, Werring DJ, Whiteley WN, Wardlaw JM, White PM (2019) Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the restart randomised, open-label trial. Lancet Neurol 18:643–652CrossRef Al-Shahi Salman R, Minks DP, Mitra D, Rodrigues MA, Bhatnagar P, du Plessis JC, Joshi Y, Dennis MS, Murray GD, Newby DE, Sandercock PAG, Sprigg N, Stephen J, Sudlow CLM, Werring DJ, Whiteley WN, Wardlaw JM, White PM (2019) Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the restart randomised, open-label trial. Lancet Neurol 18:643–652CrossRef

Zurück zum Zitat RESTART Collaboration (2019) Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (restart): a randomised, open-label trial. Lancet 393:2613–2623CrossRef RESTART Collaboration (2019) Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (restart): a randomised, open-label trial. Lancet 393:2613–2623CrossRef

Zurück zum Zitat Foreman PM, Ilyas A, Mooney J, Schmalz PGR, Walters BC, Griessenauer CJ (2018) Antiplatelet medication reversal strategies in operative intracranial hemorrhage: A survey of practicing neurosurgeons. World Neurosurg 116:e649–e654CrossRef Foreman PM, Ilyas A, Mooney J, Schmalz PGR, Walters BC, Griessenauer CJ (2018) Antiplatelet medication reversal strategies in operative intracranial hemorrhage: A survey of practicing neurosurgeons. World Neurosurg 116:e649–e654CrossRef

Zurück zum Zitat Wilson D, Ambler G, Lee KJ, Lim JS, Shiozawa M, Koga M, Li L, Lovelock C, Chabriat H, Hennerici M, Wong YK, Mak HKF, Prats-Sanchez L, Martinez-Domeno A, Inamura S, Yoshifuji K, Arsava EM, Horstmann S, Purrucker J, Lam BYK, Wong A, Kim YD, Song TJ, Schrooten M, Lemmens R, Eppinger S, Gattringer T, Uysal E, Tanriverdi Z, Bornstein NM, Assayag EB, Hallevi H, Tanaka J, Hara H, Coutts SB, Hert L, Polymeris A, Seiffge DJ, Lyrer P, Algra A, Kappelle J, Al-Shahi Salman R, Jager HR, Lip GYH, Mattle HP, Panos LD, Mas JL, Legrand L, Karayiannis C, Phan T, Gunkel S, Christ N, Abrigo J, Leung T, Chu W, Chappell F, Makin S, Hayden D, Williams DJ, Kooi ME, van Dam-Nolen DHK, Barbato C, Browning S, Wiegertjes K, Tuladhar AM, Maaijwee N, Guevarra C, Yatawara C, Mendyk AM, Delmaire C, Kohler S, van Oostenbrugge R, Zhou Y, Xu C, Hilal S, Gyanwali B, Chen C, Lou M, Staals J, Bordet R, Kandiah N, de Leeuw FE, Simister R, van der Lugt A, Kelly PJ, Wardlaw JM, Soo Y, Fluri F, Srikanth V, Calvet D, Jung S, Kwa VIH, Engelter ST, Peters N, Smith EE, Yakushiji Y, Orken DN, Fazekas F, Thijs V, Heo JH, Mok V, Veltkamp R, Ay H, Imaizumi T, Gomez-Anson B, Lau KK, Jouvent E, Rothwell PM, Toyoda K, Bae HJ, Marti-Fabregas J, Werring DJ (2019) Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: A pooled analysis of individual patient data from cohort studies. Lancet Neurol 18:653–665CrossRef Wilson D, Ambler G, Lee KJ, Lim JS, Shiozawa M, Koga M, Li L, Lovelock C, Chabriat H, Hennerici M, Wong YK, Mak HKF, Prats-Sanchez L, Martinez-Domeno A, Inamura S, Yoshifuji K, Arsava EM, Horstmann S, Purrucker J, Lam BYK, Wong A, Kim YD, Song TJ, Schrooten M, Lemmens R, Eppinger S, Gattringer T, Uysal E, Tanriverdi Z, Bornstein NM, Assayag EB, Hallevi H, Tanaka J, Hara H, Coutts SB, Hert L, Polymeris A, Seiffge DJ, Lyrer P, Algra A, Kappelle J, Al-Shahi Salman R, Jager HR, Lip GYH, Mattle HP, Panos LD, Mas JL, Legrand L, Karayiannis C, Phan T, Gunkel S, Christ N, Abrigo J, Leung T, Chu W, Chappell F, Makin S, Hayden D, Williams DJ, Kooi ME, van Dam-Nolen DHK, Barbato C, Browning S, Wiegertjes K, Tuladhar AM, Maaijwee N, Guevarra C, Yatawara C, Mendyk AM, Delmaire C, Kohler S, van Oostenbrugge R, Zhou Y, Xu C, Hilal S, Gyanwali B, Chen C, Lou M, Staals J, Bordet R, Kandiah N, de Leeuw FE, Simister R, van der Lugt A, Kelly PJ, Wardlaw JM, Soo Y, Fluri F, Srikanth V, Calvet D, Jung S, Kwa VIH, Engelter ST, Peters N, Smith EE, Yakushiji Y, Orken DN, Fazekas F, Thijs V, Heo JH, Mok V, Veltkamp R, Ay H, Imaizumi T, Gomez-Anson B, Lau KK, Jouvent E, Rothwell PM, Toyoda K, Bae HJ, Marti-Fabregas J, Werring DJ (2019) Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: A pooled analysis of individual patient data from cohort studies. Lancet Neurol 18:653–665CrossRef

Zurück zum Zitat Cannistraro RJ, Meschia JF (2018) The clinical dilemma of anticoagulation use in patients with cerebral amyloid angiopathy and atrial fibrillation. Curr Cardiol Rep 20:106CrossRef Cannistraro RJ, Meschia JF (2018) The clinical dilemma of anticoagulation use in patients with cerebral amyloid angiopathy and atrial fibrillation. Curr Cardiol Rep 20:106CrossRef

Zurück zum Zitat Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955–962CrossRef Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955–962CrossRef

Zurück zum Zitat Korompoki E, Filippidis FT, Nielsen PB, Del Giudice A, Lip GYH, Kuramatsu JB, Huttner HB, Fang J, Schulman S, Marti-Fabregas J, Gathier CS, Viswanathan A, Biffi A, Poli D, Weimar C, Malzahn U, Heuschmann P, Veltkamp R (2017) Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. Neurology 89:687–696CrossRef Korompoki E, Filippidis FT, Nielsen PB, Del Giudice A, Lip GYH, Kuramatsu JB, Huttner HB, Fang J, Schulman S, Marti-Fabregas J, Gathier CS, Viswanathan A, Biffi A, Poli D, Weimar C, Malzahn U, Heuschmann P, Veltkamp R (2017) Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. Neurology 89:687–696CrossRef

Zurück zum Zitat Pennlert J, Overholser R, Asplund K, Carlberg B, Van Rompaye B, Wiklund PG, Eriksson M (2017) Optimal timing of anticoagulant treatment after intracerebral hemorrhage in patients with atrial fibrillation. Stroke 48:314–320CrossRef Pennlert J, Overholser R, Asplund K, Carlberg B, Van Rompaye B, Wiklund PG, Eriksson M (2017) Optimal timing of anticoagulant treatment after intracerebral hemorrhage in patients with atrial fibrillation. Stroke 48:314–320CrossRef